VIVUS LLC
45
1
2
40
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
6.7%
3 terminated/withdrawn out of 45 trials
93.0%
+6.5% vs industry average
33%
15 trials in Phase 3/4
55%
22 of 40 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Role: lead
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
Role: collaborator
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
Role: lead
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
Role: lead
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
Role: lead
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
Role: collaborator
Qsymia as an Adjunct to Surgical Therapy in the Superobese
Role: collaborator
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Role: lead
Study Evaluating the Effects of Avanafil on Semen Parameters
Role: lead
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Role: lead
Safety Study Looking at the Effects of Stendra on Vision
Role: lead
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
Role: lead
VI-1121 for the Treatment Alzheimer's Disease
Role: lead
A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.
Role: lead
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
Role: lead
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
Role: lead
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
Role: lead
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
Role: lead
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
Role: lead
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
Role: lead